Semaglutide Half-Life and Pharmacokinetics

Pharmacokinetic parameters in summary

Population mean values from the FDA prescribing information and EMA EPAR. Inter-individual variability is non-trivial; consult the regulatory documents for confidence intervals and special-population data.^[2],[3],[4]

Why approximately one week?

Native GLP-1 has a plasma half-life of roughly 1 to 2 minutes. Semaglutide's engineered half-life of about 165 hours is the product of two complementary strategies working in parallel:^[1]

1. Aib8: blocking DPP-4 cleavage. DPP-4 is a ubiquitous serine protease that cleaves dipeptides from the N-terminus of peptides with alanine or proline at position 2. Native GLP-1 has alanine at position 8 (the equivalent position in the GLP-1 numbering scheme), making it an efficient DPP-4 substrate. Replacing this with alpha-aminoisobutyric acid (Aib) adds steric bulk that blocks the enzyme's active site without disrupting receptor binding. This single substitution extends enzymatic stability from minutes to hours.
2. C18 fatty diacid via gamma-Glu-2xOEG linker: albumin binding.A C18 fatty diacid is attached to lysine at position 26 (Lys26) through a spacer consisting of one gamma-glutamate and two mini-PEG units (OEG). The fatty acid chain then non-covalently but tightly binds serum albumin, which has several fatty acid binding pockets on its surface. Albumin-bound semaglutide (greater than 99 % of the total) is effectively invisible to the glomerular filtration apparatus (the albumin molecule itself has a molecular weight of approximately 67,000 daltons), and is released from albumin slowly as free drug equilibrium is maintained. This mechanism extends the half-life from hours to approximately one week.

A secondary contributor is the slow subcutaneous absorption from the depot, which means the apparent half-life observed from SC dosing is determined partly by the absorption rate (flip-flop kinetics) as well as the intrinsic elimination.

Oral semaglutide and SNAC

The oral formulation (Rybelsus) presents a fundamentally different absorption challenge. Peptides are degraded by gastric acid and proteases (pepsin, trypsin, chymotrypsin) long before reaching the intestinal mucosa, and even intact peptides cross the gut epithelium poorly. Rybelsus overcomes this by co-formulating semaglutide with SNAC(sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) at approximately 300 mg per tablet.

SNAC acts locally in the stomach. It raises the pH immediately around the dissolving tablet, protecting semaglutide from acid denaturation, and transiently loosens tight junctions and increases transcellular permeability of the gastric epithelium so that the peptide can cross into the bloodstream. The absorption window is narrow and highly condition-dependent: food in the stomach dilutes SNAC, shifts gastric pH, and substantially reduces semaglutide absorption. The prescribing information therefore requires Rybelsus to be taken on an empty stomach, with no more than 120 mL of plain water, at least 30 minutes before the first food, beverage, or other medication of the day.^[2]

Despite these constraints, the absolute oral bioavailability of approximately 1 % is sufficient for the 7 and 14 mg doses to achieve therapeutic plasma concentrations comparable to subcutaneous exposures in the T2DM indication. Half-life of oral semaglutide is the same as subcutaneous (the fatty diacid and Aib8 modifications are identical); what differs is the absorption pharmacokinetics.

Dose titration schedules

All three formulations use a gradual dose escalation to limit gastrointestinal adverse events. Steady-state plasma concentrations are not reached until 4 to 5 weeks after the start or a dose change.

Titration schedules summarized from the FDA prescribing information.^[2],[3]The 0.25 mg Ozempic dose is a starting dose only; it is not intended for glycemic control.

Special populations

• Renal impairment. No dose adjustment is required for mild, moderate, severe, or end-stage renal impairment for the subcutaneous formulations. Because semaglutide is not renally cleared (it is metabolized by proteolysis and beta-oxidation), renal function does not materially alter exposure. Caution is nonetheless warranted in patients with severe renal impairment who experience significant GI adverse events, as nausea, vomiting, and diarrhea may worsen volume depletion and affect residual renal function.
• Hepatic impairment. No dose adjustment is required across mild, moderate, or severe hepatic impairment (Child-Pugh A, B, or C) for the subcutaneous formulations. The effect of hepatic impairment on oral semaglutide absorption has not been formally studied and should be interpreted cautiously.
• Body weight. Higher body weight is associated with higher apparent volume of distribution and modestly lower steady-state concentrations, but population PK models do not support dose adjustment on the basis of body weight alone.
• Age, sex, race and ethnicity. None of these covariates require dose adjustment in regulatory PK analyses. GLP-1R agonist exposure may be modestly higher in Asian populations at equivalent doses; clinical significance is limited.
• Drug interactions. Semaglutide is not a CYP450 substrate, inhibitor, or inducer. The primary pharmacokinetic interaction of concern is delayed gastric emptying, which may alter the absorption rate of orally co-administered medications. This is particularly relevant for drugs with narrow therapeutic windows or those that depend on rapid gastric absorption (for example, some thyroid hormones and oral contraceptives). For Rybelsus specifically, other oral drugs should not be taken within 30 minutes of the semaglutide dose because they may compete with the narrow SNAC-mediated absorption window.